Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
The study is evaluating the oral inhibitor for patients with relapsed or refractory follicular lymphoma.
Researchers indicated that a lack of understanding of the mechanism and efficacy of PD-1/PD-L1 inhibitors is the major barrier for prescription of these inhibitors in Chinese tumor treatment-related departments.
The authors indicated that prospective clinical trials investigating DTIC-based systemic chemotherapies and liver-directed treatments are necessary to validate their findings.
ASCO named the advance in their annual report, Clinical Cancer Advances: ASCO’s Annual Report on Progress Against Cancer, highlighting novel advances and listing research priorities for the cancer community.
Researchers indicated that using observed incidence rates from patients with colorectal cancer alone to assess potential screening outcomes may underestimate cancer prevention benefits.
Inconsistencies observed by researchers on these websites indicated that efforts are needed to improve website content and readability.
Delivering the PDA to clients of tobacco quit lines, researchers highlighted the importance of broader dissemination and greater effect of the intervention.
Across all oncologic procedures observed in this study, the robotic approach was found to be most associated with lower out-of-pocket costs.
For the first time in 50 years, the government agency is examining asbestos testing for talc powders and cosmetics after traces of the known carcinogen were found in a number of such products.